Ipsen Unveils Corabotase as First-in-Class Recombinant Neuroinhibitor at SCALE 2026 Symposium

Ipsen's presentation of corabotase at the SCALE 2026 Symposium signals a new upstream and downstream process development challenge for biologics manufacturers: a domain-engineered recombinant protein built from two deliberately optimized functional units, each requiring distinct expression, purification, and characterization strategies under existing 21 CFR Part 211 and ICH Q10 frameworks.

Corabotase (IPN10200) combines an engineered catalytic domain A with an affinity-enhanced binding domain B. According to Ipsen, every structural element has been optimized to increase receptor affinity, enhance cellular uptake, and improve resistance to degradation, attributes that directly shape process validation scope, reference standard qualification, and comparability protocols across manufacturing scales. The WHO and USAN have recognized corabotase as the first molecule in a newly designated class: recombinant neuroinhibitors, designated RNI™.

Phase II data from the LANTIC trial (n=727), reported in September 2025, confirmed a differentiated clinical profile in glabellar lines, with rapid onset and sustained duration of effect. The trial is structured across three stages: Stage 1 covered dose-finding and dose-escalation in glabellar lines across three steps, with Step 3, the proof-of-concept basis, enrolling 183 patients. Stages 2 and 3 will extend evaluation to forehead lines and lateral canthal lines versus placebo, with proof-of-concept data expected later in 2026.

For QA directors and regulatory affairs leads, the first-in-class designation introduces a regulatory pathway with limited precedent. Characterization packages for a novel RNI will need to establish class-level comparators from the ground up, with no established reference product against which to benchmark potency assays or immunogenicity risk assessments. Ipsen's proprietary manufacturing platform is central to this program, but the absence of a predicate molecule means that process-related impurity profiles and release specifications will require extensive justification in the biologics license application dossier.

A broad Phase II and Phase III program is advancing corabotase across both aesthetic and therapeutic indications, expanding the manufacturing and regulatory surface area considerably as the program scales.

The proof-of-concept readout for forehead and lateral canthal lines, expected later in 2026, will be the next measurable checkpoint for teams assessing process scalability and regulatory strategy alignment ahead of potential Phase III manufacturing commitments.

Source: Ipsen via GlobeNewswire, 14 May 2026.